CD226 and breast carcinoma: Although the number of patients screened for the breast cancer transcriptomic study was small, survival analyses performed on a larger number of breast cancer patients (n = 115) derived from four publicly available breast cancer datasets of gene expression [29-32] revealed a significantly (p < 0.03) better survival for patients that showed higher expression of the NCR3 (NKp30), NCR1 (NKp46), CD96, CRTAM, DNAM1 and NKG2D.